2. Keetile N.M., Osuch E., Lentoor A.G. Chemotherapy-related subjective cognitive impairment in breast cancer patients in semi-rural South Africa. Health SA. 2021; 26: 1605. https://dx.doi.org/10.4102/hsag.v26i0.1605.

3. Duran-Gomez N., Lopez-Jurado C.F., Nadal-Delgado M. et al. Chemotherapy-related cognitive impairment in patients with breast cancer based on functional assessment and NIRS analysis. J Clin Med. 2022; 11(9): 2363. https://dx.doi.org/10.3390/jcm11092363.

4. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209–49. https://dx.doi.org/10.3322/caac.21660.

5. Johnson R.H., Anders C.K., Litton J.K. et al. Breast cancer in adolescents and young adults. Pediatr Blood Cancer. 2018; 65(12): e27397. https://dx.doi.org/10.1002/pbc.27397.

6. Wilkinson L., Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022; 95(1130): 20211033. https://dx.doi.org/10.1259/bjr.20211033.

7. Konat-Baska K., Matkowski R., Błaszczyk J. et al. Does breast cancer increasingly affect younger women? Int J Environ Res Public Health. 2020; 17(13): 4884. https://dx.doi.org/10.3390/ijerph17134884.

8. Syarif H., Waluyo A., Afiyanti Y. Cognitive perception among post-chemotherapy, non-chemotherapy breast cancer survivors and non-cancer. Asian Pac J Cancer Prev. 2021; 22(6): 1775–80. https://dx.doi.org/10.31557/APJCP.2021.22.6.1775.

9. Ibrahim E.Y., Domenicano I., Nyhan K. et al. Cognitive effects and depression associated with taxane-based chemotherapy in breast cancer survivors: A meta-analysis. Front Oncol. 2021; 11: 642382. https://dx.doi.org/10.3389/fonc.2021.642382.

10. Abebe E., Tollesa T., Assefa M. et al. Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: An institution-based comparative cross-sectional study. BMC Cancer. 2021; 21(1): 1052. https://dx.doi.org/10.1186/s12885-021-08799-0.

11. Lin K.Y., Chen V.C., Tsai Y.H. et al. Classification and visualization of chemotherapy-induced cognitive impairment in volumetric convolutional neural networks. J Pers Med. 2021; 11(10): 1025. https://dx.doi.org/10.3390/jpm11101025.

12. Corley C., Allen A.R. A bibliometric analysis of cyclophosphamide, methotrexate, and fluorouracil breast cancer treatments: Implication for the role of inflammation in cognitive dysfunction. Front Mol Biosci. 2021; 8: 683389. https://dx.doi.org/10.3389/fmolb.2021.683389.

13. Zhang Q., Gao X., Liu S. et al. Therapies for cognitive impairment in breast cancer survivors treated with chemotherapy: A protocol for systematic review. Medicine (Baltimore). 2020; 99(19): e20092. https://dx.doi.org/10.1097/MD.0000000000020092.

14. Wagner L.I., Gray R.J., Sparano J.A. et al. Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: Results from TAILORx. J Clin Oncol. 2020; 38(17): 1875–86. https://dx.doi.org/10.1200/JCO.19.01866.

15. Rodriguez Martin B., Fernandez Rodriguez E.J., Rihuete Galve M.I., Cruz Hernandez J.J. Study of chemotherapy-induced cognitive impairment in women with breast cancer. Int J Environ Res Public Health. 2020; 17(23): 8896. https://dx.doi.org/10.3390/ijerph17238896.

16. Huehnchen P., van Kampen A., Boehmerle W., Endres M. Cognitive impairment after cytotoxic chemotherapy. Neurooncol Pract. 2020; 7(1): 11–21. https://dx.doi.org/10.1093/nop/npz052.

17. Van der Gucht K., Melis M., Ahmadoun S. et al. A mindfulness-based intervention for breast cancer patients with cognitive impairment after chemotherapy: study protocol of a three-group randomized controlled trial. Trials. 2020; 21(1): 290. https://dx.doi.org/10.1186/s13063-020-4204-8.

18. Hormozi M., Hashemi S.M., Shahraki S. Investigating relationship between pre- and post- chemotherapy cognitive performance with levels of depression and anxiety in breast cancer patients: A cross-sectional study. Asian Pac J Cancer Prev. 2019; 20(12): 3831–37. https://dx.doi.org/10.31557/APJCP.2019.20.12.3831.

19. Li Z., Hao X., Lei P. et al. Patients with breast cancer receiving chemotherapy: Effects of multisensory stimulation training on cognitive impairment. Clin J Oncol Nurs. 2022; 26(1): 71–77. https://dx.doi.org/10.1188/22.CJON.71-77.

20. Yu S., Zhao J., Wang M. et al. The correlation between neutrophil-to-lymphocyte ratio, carcinoembryonic antigen, and carbohydrate antigen 153 levels with chemotherapy-related cognitive impairment in early-stage breast cancer patients. Front Med (Lausanne). 2022; 9: 945433. https://dx.doi.org/10.3389/fmed.2022.945433.

21. Von Ah D., Crouch A.D., Monahan P.O. et al. Association of cognitive impairment and breast cancer survivorship on quality of life in younger breast cancer survivors. J Cancer Surviv. 2022; 16(4): 812–22. https://dx.doi.org/10.1007/s11764-021-01075-x.

22. West T., Cavallero C., Ceccherini R. et al. Impact of psychosocial, behavioral and lifestyle factors on subjective cognitive complaints and perceived quality of life in a large cohort of Italian breast cancer patients. Front Psychol. 2022; 13: 1015573. https://dx.doi.org/10.3389/fpsyg.2022.1015573.

23. Carreira H., Williams R., Dempsey H. et al. Quality of life and mental health in breast cancer survivors compared with non-cancer controls: A study of patient-reported outcomes in the United Kingdom. J Cancer Surviv. 2021; 15(4): 564–75. https://dx.doi.org/10.1007/s11764-020-00950-3.

24. Ganz P.A., Van Dyk K. Cognitive Impairment in Patients With Breast Cancer: Understanding the impact of chemotherapy and endocrine therapy. J Clin Oncol. 2020; 38(17): 1871–74. https://dx.doi.org/10.1200/JCO.20.00336.

25. Orszaghova Z., Mego M., Chovanec M. Long-term cognitive dysfunction in cancer survivors. Front Mol Biosci. 2021; 8: 770413. https://dx.doi.org/10.3389/fmolb.2021.770413

26. Hajj A., Khoury R., Hachem R. et al. Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: The «CAGE-Cog» study. BMC Cancer. 2022; 22(1): 996. https://dx.doi.org/10.1186/s12885-022-10077-6.

27. Vega J.N., Dumas J., Newhouse P.A. Self-reported chemotherapy-related cognitive impairment compared with cognitive complaints following menopause. Psychooncology. 2018; 27(9): 2198–205. https://dx.doi.org/10.1002/pon.4796.

28. Khan O.F., Cusano E., Raissouni S. et al. Immediate-term cognitive impairment following intravenous (IV) chemotherapy: A prospective pre-post design study. BMC Cancer. 2019; 19(1): 150. https://dx.doi.org/10.1186/s12885-019-5349-2.

29. Lange M., Joly F., Vardy J. et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019; 30(12): 1925–40. https://dx.doi.org/10.1093/annonc/mdz410.

30. Liou K.T., Ahles T.A., Garland S.N. et al. The relationship between insomnia and cognitive impairment in breast cancer survivors. JNCI Cancer Spectr. 2019; 3(3): pkz041. https://dx.doi.org/10.1093/jncics/pkz041.

31. Rodriguez N., Fawcett J.M., Rash J.A. et al. Factors associated with cognitive impairment during the first year of treatment for nonmetastatic breast cancer. Cancer Med. 2021; 10(4): 1191–200. https://dx.doi.org/10.1002/cam4.3715.

32. Ancoli-Israel S., Liu L., Natarajan L. et al. Reductions in sleep quality and circadian activity rhythmicity predict longitudinal changes in objective and subjective cognitive functioning in women treated for breast cancer. Support Care Cancer. 2022; 30(4): 3187–200. https://dx.doi.org/10.1007/s00520-021-06743-3.

33. Martin C., Shrestha A., Morgan J. et al. Treatment choices for older women with primary operable breast cancer and cognitive impairment: Results from a prospective, multicentre cohort study. J Geriatr Oncol. 2021; 12(5): 705–13. https://dx.doi.org/10.1016/j.jgo.2020.12.006.

34. Magnuson A., Lei L., Gilmore N. et al. Longitudinal relationship between frailty and cognition in patients 50 years and older with breast cancer. J Am Geriatr Soc. 2019; 67(5): 928–36. https://dx.doi.org/10.1111/jgs.15934.

35. Whittaker A.L., George R.P., O’Malley L. Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: A systematic review and meta-analysis. Sci Rep. 2022; 12(1): 2135. https://dx.doi.org/10.1038/s41598-022-05682-1.

36. Gan C., Lv Y., Zhao J. et al. Neural correlates of chemotherapy-induced emotion regulation impairment in breast cancer patients. Am J Cancer Res. 2019; 9(1): 171–79.

37. Sahu K., Langeh U., Singh C., Singh A. Crosstalk between anticancer drugs and mitochondrial functions. Curr Res Pharmacol Drug Discov. 2021; 2: 100047. https://dx.doi.org/10.1016/j.crphar.2021.100047.

38. Carlson B.W., Craft M.A., Carlson J.R. et al. Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. 2018; 40(3): 325–36. https://dx.doi.org/10.1007/s11357-018-0025-z.

39. Papanastasiou A., Seliniotaki T., Rizos E. et al. Role of stress, age and adjuvant therapy in the cognitive function of patients with breast cancer. Oncol Lett. 2019; 18(1): 507–17. https://dx.doi.org/10.3892/ol.2019.10361.

40. Hajj A., Hachem R., Khoury R. et al. Clinical and genetic factors associated with anxiety and depression in breast cancer patients: A cross-sectional study. BMC Cancer. 2021; 21(1): 872. https://dx.doi.org/10.1186/s12885-021-08615-9.

41. Li W., Zhang Q., Cai Y. et al. The COMT genetic factor regulates chemotherapy-related prospective memory impairment in survivors with HER2-/+ breast cancer. Front Oncol. 2022; 12: 816923. https://dx.doi.org/10.3389/fonc.2022.816923.

42. Harrison R.A., Rao V., Kesler S.R. The association of genetic polymorphisms with neuroconnectivity in breast cancer patients. Sci Rep. 2021; 11(1): 6169. https://dx.doi.org/10.1038/s41598-021-85768-4.

43. Van Dyk K., Zhou X., Small B.J. et al. Protective effects of APOE ε2 genotype on cognition in older breast cancer survivors: The thinking and living with cancer study. JNCI Cancer Spectr. 2021; 5(2): pkab013. https://dx.doi.org/10.1093/jncics/pkab013.

44. Bilenduke E., Sterrett J.D., Ranby K.W. et al. Impacts of breast cancer and chemotherapy on gut microbiome, cognitive functioning, and mood relative to healthy controls. Sci Rep. 2022; 12(1): 19547. https://dx.doi.org/10.1038/s41598-022-23793-7.

45. Yao S., Li W., Liu S. et al. Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy-related cognitive impairment in patients with breast cancer who receive chemotherapy. Cancer Med. 2023; 12(5): 5209–21. https://dx.doi.org/10.1002/cam4.5319.

46. Cui H., Shi X., Song X., Zhang W. Changes and influencing factors of cognitive impairment in patients with breast cancer. Evid Based Complement Alternat Med. 2021; 2021: 7278853. https://dx.doi.org/10.1155/2021/7278853.

47. Boscher C., Joly F., Clarisse B. et al. Perceived cognitive impairment in breast cancer survivors and its relationships with psychological factors. Cancers (Basel). 2020; 12(10): 3000. https://dx.doi.org/10.3390/cancers12103000.

48. Koh Y.Q., Ng D.Q., Ng C.C. et al. Extracellular vesicle proteome of breast cancer patients with and without cognitive impairment following anthracycline-based chemotherapy: An exploratory study. Biomark Insights. 2021; 16: 11772719211018204. https://dx.doi.org/10.1177/11772719211018204.

49. Zhou X., Tan Y., Yu H. et al. Early alterations in cortical morphology after neoadjuvant chemotherapy in breast cancer patients: A longitudinal magnetic resonance imaging study. Hum Brain Mapp. 2022; 43(15): 4513–28. https://dx.doi.org/10.1002/hbm.25969.

50. Palmer A.C.S., Zortea M., Souza A. et al. Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; Effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial. PLoS One. 2020; 15(4): e0231379. https://dx.doi.org/10.1371/journal.pone.0231379.